Navigation Links
AtheroNova Completes Successful Pre-IND Meeting with FDA on AHRO-001
Date:10/26/2011

t sectors potentially served by AHRO-001 include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the Company's pipeline, milestones, future filings and trials, markets, mechanisms of action, licensing agreements and equity investment as well as the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Research and Markets  has announced ... Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal ... http://photos.prnewswire.com/prnh/20130307/600769 ... in IVD testing with competitive participation by top ... criminal justice personnel, and sports use drug tests ...
(Date:8/1/2014)... 1, 2014 Aspire Technology Partners (Aspire) announced today ... from Cisco. This designation recognizes Aspire for delivering outstanding customer ... America . "Achieving exceptional results for our ... Harris , President and CEO of Aspire. "We are pleased ... Gold Star award and are proud to be part of ...
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
Breaking Medicine Technology:Drugs of Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets) 2Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2
... Mass. , Feb. 4 Recognizing that corporate ... they contain, Northern Light ( www.northernlight.com ) today announced that ... excess of $2 billion can be searched, analyzed ... been steadily increasing the number of market research sources integrated ...
... N.C. , Feb. 4 Gorbec Pharmaceutical ... prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory ... expand Gorbec,s current services for analytical method development and ... its U.S. customer base as well as develop a ...
Cached Medicine Technology:Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 2Northern Light Surpasses $2 Billion Worth of Research Content Integrated Into SinglePoint Strategic Research Portals 3Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China 2
(Date:8/1/2014)... Cannabis use among young people has spiked, with 29.3 ... marijuana at least once and 17 percent admitting to regular ... Say ‘Yes to Life,’ volunteers from the Church of Scientology ... factual information about drugs, to help reverse this alarming trend. ... Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 copies ...
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... appetite and whole-body metabolism. A protein known as PPARγ ... and body weight, but the identity of the neurons ... new study in the Journal of Clinical Investigation ... neuron known as pro-opiomelanocortin (POMC) neurons is critical in ... and colleagues at Yale University School of Medicine found ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2
... ... and expand, it has taken steps to further strengthen its relationship with ... government procurement system. Government agencies have always been a valuable part of ... will greatly facilitate the contracting of radio public relations services in the ...
... WEDNESDAY, Feb. 3 (HealthDay News) -- New British research suggests that ... in better shape than those who walk and take buses or ... of physical tests and questionnaires given to 6,000 children, ages 10 ... They found that boys who walked to school were 20 percent ...
... ... states AidRight.com , ... (PRWEB) February 2, 2010 -- AidRight Hearing Aids recommends looking for a complete service ... ensures total satisfaction. Although it is possible to purchase hearing aids without personalization and ...
... , ... Awareness Month this February, Dr. Sheldon Smith , optometrist at Low ... diagnosed with retinitis pigmentosa (RP), a leading cause of low vision, in ... enhance or restore sight. , Until recently, very little was available ...
... , DALLAS , Feb. 3 Too many women ... No. 1 killer. Right now, one in three women die of cardiovascular ... for developing heart disease in the future. On February 5 , ... nationwide call for stories and inviting women to Speak Up about heart ...
... ... schedules of industry expert speakers ever assembled to address HIMSS 2010 attendees , ... (PRWEB) February 3, 2010 ... solutions, has developed one of the most significant schedules of industry expert speakers ever ...
Cached Medicine News:Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 2Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 3Health News:AidRight Hearing Aids Tells Consumers to Order Professional Care with That Hearing Aid 2Health News:Livonia Optometrist Offers New Technology - and New Hope - to Patients ... Free of Charge 2Health News:Livonia Optometrist Offers New Technology - and New Hope - to Patients ... Free of Charge 3Health News:Go Red For Women(R) and Jennie Garth Ask Women to Speak Up About Their No. 1 Killer 2Health News:Go Red For Women(R) and Jennie Garth Ask Women to Speak Up About Their No. 1 Killer 3Health News:Go Red For Women(R) and Jennie Garth Ask Women to Speak Up About Their No. 1 Killer 4Health News:Sunquest Announces Significant Speaker Schedule for HIMSS 2010 2Health News:Sunquest Announces Significant Speaker Schedule for HIMSS 2010 3Health News:Sunquest Announces Significant Speaker Schedule for HIMSS 2010 4
... utilizes allele-specific primer combinations in the PCR ... that only primers whose sequence is completely ... converted by the polymerase into PCR products. ... product. Using the Biotest SSP Kit Systems, ...
... bags as in a suspension file system, in ... the ethylene glycol and without having to lift ... handling and maximum surface freezing concurrently with sealing ... hot air under the lid does not obstruct ...
Helmer offers Plasma Storage Freezer lines, the i.Series ipf 125-8. It is Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost tim...
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...
Medicine Products: